Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
299.31B
Market cap299.31B
Price-Earnings ratio
33.69
Price-Earnings ratio33.69
Dividend yield
2.77%
Dividend yield2.77%
Average volume
8.94M
Average volume8.94M
High today
$122.37
High today$122.37
Low today
$119.56
Low today$119.56
Open price
$120.00
Open price$120.00
Volume
2.83M
Volume2.83M
52 Week high
$125.14
52 Week high$125.14
52 Week low
$75.40
52 Week low$75.40

Stock Snapshot

Merck(MRK) stock is priced at $121.19, giving the company a market capitalization of 299.31B. It carries a P/E multiple of 33.69 and pays a dividend yield of 2.8%.

On 2026-05-27, Merck(MRK) stock moved within a range of $119.56 to $122.37. With shares now at $121.19, the stock is trading +1.4% above its intraday low and -1.0% below the session's peak.

Trading volume for Merck(MRK) stock has reached 2.83M, versus its average volume of 8.94M.

The stock's 52-week range extends from a low of $75.40 to a high of $125.14.

The stock's 52-week range extends from a low of $75.40 to a high of $125.14.

MRK News

Simply Wall St 2h
Merck’s Expanding Oncology Suite And Fresh Debt Raise Might Change The Case For Investing In MRK

In May 2026, Merck & Co., Inc. received a positive CHMP opinion backing KEYTRUDA plus Padcev for certain bladder cancer patients in Europe and reported successf...

Merck’s Expanding Oncology Suite And Fresh Debt Raise Might Change The Case For Investing In MRK
MarketWatch 20h
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

...

Merck & Co. Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Simply Wall St 1d
Merck Faces Talc Verdict Questions For Future Legal And Earnings Risks

Minnesota jury issues a $10.2 million mesothelioma verdict linked to asbestos in talc products. Merck (NYSE:MRK) is named as a co-defendant through historical...

Merck Faces Talc Verdict Questions For Future Legal And Earnings Risks

Analyst ratings

70%

of 30 ratings
Buy
70%
Hold
30%
Sell
0%

More MRK News

TipRanks 5d
Merck Completes $6 Billion Multi-Tranche Senior Notes Offering

Start a conversation with TipRanks’ trusted, data-backed investment intelligence Ask Samuel about stocks, your portfolio, or the market and get instant, person...

The Motley Fool 5d
Healthcare Stocks Are on Fire -- Don't Miss These Opportunities

The healthcare sector just had its best week in six months. The State Street Health Care Select Sector SPDR ETF (XLV +1.17%), which tracks the healthcare sector...

Healthcare Stocks Are on Fire -- Don't Miss These Opportunities
Simply Wall St 5d
Merck Valuation Check After Key Oncology Trial Success And Positive EU Opinion

Merck (MRK) has drawn fresh attention after reporting Phase 3 success for its investigational antibody drug conjugate sacituzumab tirumotecan in advanced or rec...

Merck Valuation Check After Key Oncology Trial Success And Positive EU Opinion
Barron's 5d
Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.

Biotech and Pharma Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony. In this article MRK 6990 SPX PFE 4503 Merck and Sichuan K...

Merck Stock Climbs on Cancer Data. Why the Drugmaker Is More Than a One-Trick Pony.
TipRanks 5d
Merck receives positive CHMP opinion for KEYTRUDA plus Padcev

Merck (MRK) announced the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval of KEYTRUD...

Seeking Alpha 5d
Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial

Chinese biopharma company Kelun-Biotech announced on Thursday that an antibody drug conjugate it is developing with Merck (MRK), with Keytruda, outperformed the...

Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.